Under the deal, Lupus Therapeutics will aid with patient recruitment, trial site activation and engagement through the Lupus Clinical Investigators Network, the company said in a Tuesday release.
Current lupus treatments include GSK’s SLE drug Benlysta, a biologic therapy approved by the FDA in 2011, and AstraZeneca’s Saphnelo, an IV infusion that garnered approval for patients with SLE in 2021.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.